EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting BCR-ABL1-positive leukaemias: a review article

Steven Leak, Gillian A Horne, Mhairi Copland iD

Cambridge Prisms: Precision Medicine · 2023 · 1

DOI: 10.1017/pcm.2023.9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cambridge Prisms: Precision Medicine, online erschienen am 06.03.2023. Verfasst von Steven Leak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Glasgow.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment and understanding of BCR::ABL1-positive leukaemias is a precision medicine success story. Our appreciation of the BCR::ABL1 gene and resulting BCR::ABL1 oncoprotein in chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive (Ph+) acute leukaemias, has led to treatment advances associated with exceptional improvements in patient outcomes with normal life expectancy for many patients with chronic phase (CP-)CML. However, despite these major therapeutic advances, the management of Ph+ leukaemias remains complex, with development of specific resistance mutations on treatment, as well as the need for lifelong therapy in most patients due to the persistence of CML stem cells despite prolonged tyrosine kinase inhibitors (TKIs) treatment. BCR::ABL1-specific TKIs are associated with chronic toxicities affecting quality-of-life in many patients but can also result in more serious pulmonary and cardiovascular complications. Dose optimisation is increasingly being used to manage side effects and maintain molecular response in CML patients. Here, we review the development of BCR::ABL1-specific TKIs from the discovery of imatinib in 1996 to the more recent second- and third-generation TKIs and emerging specifically targeting the ABL myristoyl pocket (STAMP) inhibitors. We will also evaluate the current evidence for treatment of BCR::ABL1-positive leukaemias, including TKI discontinuation in optimally responding CP-CML patients.

Schlagwörter

Stichwörter der Autor:innen

BCR::ABL1Chronic myeloid leukaemialeukaemia stem celltyrosine kinase inhibitor

Autor:innen und Institutionen

  • Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK.
  • Paul O'Gorman Leukaemia Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.

ORCID-Profile: Mhairi Copland

Förderung

  • University of Glasgow

Zitieren

APA

Leak, S., Horne, G. A., & Copland, M. (2023). Targeting BCR-ABL1-positive leukaemias: a review article. Cambridge Prisms: Precision Medicine, 1. https://doi.org/10.1017/pcm.2023.9

Vancouver

Leak S, Horne GA, Copland M. Targeting BCR-ABL1-positive leukaemias: a review article. Cambridge Prisms: Precision Medicine. 2023;1. doi:10.1017/pcm.2023.9

BibTeX
@article{Leak2023,
  author = {Leak, Steven and Horne, Gillian A and Copland, Mhairi},
  title = {Targeting BCR-ABL1-positive leukaemias: a review article},
  journal = {Cambridge Prisms: Precision Medicine},
  year = {2023},
  volume = {1},
  doi = {10.1017/pcm.2023.9}
}
Kostenlos starten →